What Trump’s Executive Order Means for Childhood Vaccinations
The order reduces the number of childhood vaccines recommendations and separates measles, mumps, and rubella into different shots.
Source: Council on Foreign Relations · August 14, 2026 at 4:08 AM · AI-assisted report
Opinion
KUALA LUMPUR, 14 AUGUST 2026 —
WASHINGTON — President Donald Trump signed an executive order on Monday directing changes to U.S. childhood vaccine recommendations, reducing the number of diseases covered from 17 to 11 and proposing that the measles, mumps, and rubella (MMR) vaccine be administered as three separate shots instead of one combined dose.
Market Impact
The order, which requires implementation by the Centers for Disease Control and Prevention (CDC) and the Advisory Committee on Immunization Practices (ACIP), marks a shift from established public health protocols to a politically driven approach. Current U.S. recommendations cover vaccines for 17 diseases, aligning with most developed nations. For example, many European countries recommend vaccines for 15 or more diseases, while Denmark recommends 10.
These variations reflect differences in disease prevalence, population demographics, and healthcare system structures.
Under the new order, the U.S. would recommend vaccines for 11 diseases, though the specific list of diseases has not yet been detailed. The proposal to split the MMR vaccine into separate doses is particularly notable, as no such single-antigen vaccines are currently approved for use in the U.S. The last standalone MMR vaccines, produced by Merck, were discontinued in 2009–2010 due to the widespread use of the combined MMR vaccine.
Reintroducing separate doses could take years and may increase costs for families, as multiple doctor visits would be required. Historically, Japan tested a similar approach in the 1990s, which led to increased outbreaks of measles, mumps, and rubella.
The executive order also allows for additional immunizations for high-risk groups or at the discretion of parents and doctors, further deviating from the standardized, evidence-based schedule currently in place. As of now, the CDC and ACIP have not adopted these recommendations, and no changes to the existing vaccination schedule have been made.
The potential impact on vaccine manufacturers remains uncertain. Merck, the sole U.S. producer of MMR vaccines, would need to decide whether to reintroduce single-antigen versions. However, given strong public support for routine childhood vaccinations and the political uncertainty surrounding the order, manufacturers may delay or avoid such investments. Any disruption to the current vaccine schedule could lead to lower vaccination rates and increased disease outbreaks.
The order raises broader concerns about U.S. leadership in global public health. Historically, the U.S. has been a leader in vaccine research, development, and regulatory systems, with its expertise trusted worldwide. A shift away from evidence-based decision-making could discourage innovation and undermine America’s credibility in future health emergencies. Other countries may also reconsider their own vaccine guidance based on these changes, potentially reversing decades of progress in reducing child mortality.
The Council on Foreign Relations, which published the analysis, emphasizes that the views expressed are those of the author and do not represent institutional policy.